Stock CLSD CLEARSIDE BIOMEDICAL, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Press Releases Clearside Biomedical, Inc.

Equities

CLSD

US1850631045

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-05-23 pm EDT 		5-day change 1st Jan Change
1.36 USD +0.74% Intraday chart for Clearside Biomedical, Inc. +3.03% +16.24%
May. 13 HC Wainwright Adjusts Price Target on Clearside Biomedical to $5 From $6, Keeps Buy Rating MT
May. 09 Transcript : Clearside Biomedical, Inc., Q1 2024 Earnings Call, May 09, 2024

Press Releases

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Clearside Biomedical Announces Publication of Consensus Guidelines for Drug Delivery via Suprachoroidal Space Injection in Leading Peer-Reviewed Industry Journal, RETINA
AQ
Clearside Biomedical Announces Publication of Consensus Guidelines for Drug Delivery via Suprachoroidal Space (SCS®) Injection in Leading Peer-Reviewed Industry Journal, RETINA®
AQ
Clearside Biomedical Announces First Quarter 2024 Financial Results and Provides Corporate Update
AQ
Clearside Biomedical to Participate in Fireside Chat at the Citizens JMP Life Sciences Conference
AQ
Clearside Biomedical to Report First Quarter 2024 Financial Results and Provide Corporate Update on Thursday, May 9, 2024
AQ
Clearside Biomedical Appoints Seasoned Biotechnology Executive Anthony S. Gibney to its Board of Directors
AQ
Clearside Biomedical to Participate in Fireside Chat at the 23rd Annual Needham Virtual Healthcare Conference
AQ
Clearside Biomedical Appoints Victor Chong, M.D., MBA as Chief Medical Officer
AQ
Clearside Biomedical Announces Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update
AQ
Clearside Biomedical to Report Fourth Quarter and Full Year 2023 Financial Results and Provide Corporate Update on Tuesday, March 12, 2024
AQ
Clearside Biomedical Announces Pricing of $15 Million Registered Direct Offering
AQ
Clearside Biomedical Reports Significant Progress in ODYSSEY Phase 2b Trial of CLS-AX in Wet AMD
AQ
Clearside Biomedical Announces Third Quarter 2023 Financial Results and Provides Corporate Update
AQ
Clearside Biomedical to Participate in Fireside Chat at the Stifel 2023 Healthcare Conference
AQ
Clearside Biomedical’s Versatile Suprachoroidal Injection Platform Highlighted in Four Ophthalmic Indications in Clinical Data Presentations at AAO 2023 Annual Meeting
AQ
BioCryst and Clearside Biomedical Enter Partnership to Develop Avoralstat for Diabetic Macular Edema Using Clearside’s Proprietary SCS Microinjector®
AQ
Clearside Biomedical Announces Presentations at the American Academy of Ophthalmology 2023 Annual Meeting
AQ
Clearside Biomedical Completes Recruitment in ODYSSEY Phase 2b Clinical Trial of CLS-AX in Wet AMD
AQ
Clearside Biomedical to Report Third Quarter 2023 Financial Results and Provide Corporate Update on Monday, November 13, 2023
AQ
Clearside Biomedical Positive OASIS and Extension Study Data Presented at The Retina Society 56th Annual Scientific Meeting
AQ
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. CLSD Stock
  4. News Clearside Biomedical, Inc.
  5. Press Releases